and enhance patient adherence by identifying primary pain mechanisms. This course will offer practical tips for evaluation of patients with mixed pain mechanism presentations and includes an interactive discussion of multimodal treatment options for each.
analgesic topics such as nmda, trk-a, nos, beta-arrestin, orl-1, kappa, gaba, liposomes, and more!
SIS-30 The Cracked Mirror:
Exploring Opioid Abuse Deterrent Methods from the Laboratory to the Real User
SIS-28 Opioid Moderatism:
Beatrice Setnik phd
Friday, September 6 Level 4 Nolita 3
Seeking Middle Ground Michael E. Schatman phd, cpe, daspe
Friday, September 6 Level 4 Nolita 3
4:40p – 5:30p
Few would question the severity of the prescription
opioid crisis of the early years of this millennium, the causes of which were myriad. Undoubtedly, society needed to address the crisis in an aggressive manner. Unfortunately, the manner in which the problem was addressed has been a classic example of overkill, resulting in a war on opioid analgesia, the patients who require opioid treatment, and the providers who have continued to prescribe. Although many have cast blame on the 2016 cdc opioid prescribing Guideline, it was not necessarily the Guideline itself that caused so much suffering, but rather its weaponization. Irrespective, patients have been the “collateral damage” in this war on opioids. This presentation will address the imperative of physicians exercising more thorough and consistent opioid risk mitigation in order to avoid opioid analgesia from becoming further “legislated away,” as well as the imperative of those who are “pro-opioid” and “anti-opioid” to agree on a rational middle ground that is more “pro-patient.”
SIS-29 Analgesics of the Future Jeffrey A. Gudin md
Friday, September 6 Level 4 Nolita 1
5:40p – 6:30p
Abuse potential is rapidly changing with evolving regula-
tory requirements for clinical methodology. Prescription drug abuse continues to be a great concern and regulatory agencies (such as the fda) require abuse potential evaluation to inform appropriate drug scheduling for novel cns drugs. In addition, many pharmaceutical companies have been developing abuse deterrent formulations to address the concerns of prescription opioid abuse. The methods to deter abuse have evolved over time and include various approaches including mitigating overdose when multiple tablets are combined with various unpleasant excipients such as gelling, strong dyes, or smells or tastes. While most of the exploration of the effectiveness of these techniques is carried out in test tubes or in a limited number of recreational drug users, this session will discuss the challenges and limitations of in vitro and in vivo studies and will engage in a discussion with actual recreational drug users to determine what their experiences are with existing marketed abuse deterrent formulations and what would most dissuade them from engaging with an abuse deterrent opioid. Both the scientists’ and recreational drug users’ perspectives will be openly discussed in this exciting and novel forum. This dynamic session will provide a unique perspective around the behaviors of recreational drug users, and better inform in vitro and in vivo testing approaches.
4:40p – 5:30p
Medicine and science builds and grows on the founda-
tions of what has come before. Although pain management discoveries have been at a relative snail’s pace, there have been recent advances in existing medications and analgesic devices, as well as exciting new molecules and formulations on the horizon. With progressive changes in technology come advances in medicine. Inasmuch, this lecture will discuss newer formulations of older molecules (nsaids, local anesthetics, opioids, gabapentinoids), touch on progress in the abuse deterrent opioid space, and introduce some exciting animal-based, preclinical, and early phase molecules in development. Come hear a discussion of the future of
SIS-31 Let’s Get on the Same Prescribing Page:
Standardizing Opioid Prescribing Practices Among Sickle Cell Disease Patients Collin V. Montgomery aprn Leigh Ann Wilson lcsw
Saturday, September 7 Level 3 Gracia 1
7:30a – 8:20a
This presentation will focus on the development of a
clinical decision tool to standardize opioid prescribing for patients with sickle cell disease. Pain is the hallmark symptom of sickle cell disease, which is often managed by hematologists or primary care physicians.
109